Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis.
Gupta M, Wells C, Regan MM, Xie W, Navani V, Saliby RM, Basappa NS, Donskov F, Yuasa T, Takemura K, Kollmannsberger CK, Crumbaker M, Lalani AA, Powles T, Ebrahimi H, McKay RR, Lee JL, Kanesvaran R, Choueiri TK, Heng DYC. Gupta M, et al. Among authors: powles t. Eur Urol Oncol. 2024 Dec 31:S2588-9311(24)00293-1. doi: 10.1016/j.euo.2024.12.011. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39743422
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
Grünwald V, McKay RR, Buchler T, Eto M, Park SH, Takagi T, Zanetta S, Keizman D, Suárez C, Négrier S, Lee JL, Santini D, Bedke J, Staehler M, Kollmannsberger C, Choueiri TK, Motzer RJ, Burgents JE, Xie R, Okpara CE, Powles T. Grünwald V, et al. Among authors: powles t. Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35288. Online ahead of print. Int J Cancer. 2024. PMID: 39739622
Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab.
Morgans AK, Sonpavde GP, Shih V, Wright P, Hepp Z, Willmon CL, Chang NN, Mucha L, Naga SSB, Powles T. Morgans AK, et al. Among authors: powles t. Clin Genitourin Cancer. 2024 Nov 15;23(1):102270. doi: 10.1016/j.clgc.2024.102270. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39662152 Free article.
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Moreno BH, Bavle A, Özgüroğlu M. Powles T, et al. Clin Genitourin Cancer. 2024 Nov 1;23(1):102261. doi: 10.1016/j.clgc.2024.102261. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39642775
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.
Rosenberg JE, Galsky MD, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, van der Heijden MS, Dreicer R, Durán I, Castellano D, Drakaki A, Retz M, Sridhar SS, Grivas P, Yu EY, O'Donnell PH, Burris HA, Mariathasan S, Shi Y, Goluboff E, Bajorin D. Rosenberg JE, et al. Among authors: powles t. ESMO Open. 2024 Dec;9(12):103972. doi: 10.1016/j.esmoop.2024.103972. Epub 2024 Dec 5. ESMO Open. 2024. PMID: 39642637 Free PMC article. Clinical Trial.
Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial.
Mamtani R, Matsubara N, Pino AM, Herranz UA, Şendur MAN, Gravis G, Huillard O, Lee HJ, Gafanov R, Joly F, Bedke J, Sella A, Chang YH, Imai K, Moreno BH, Xu JZ, Alva A, Powles T. Mamtani R, et al. Among authors: powles t. Clin Genitourin Cancer. 2024 Oct 28;23(1):102248. doi: 10.1016/j.clgc.2024.102248. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39579409 Free article.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, Koeppen H, Assaf ZJ, Nabet BY, Waddell A, Yuen K, Maund S, Sokol E, Giltnane JM, Schedlbauer A, Fuentes E, Cowan JD, Kadel EE 3rd, Degaonkar V, Andreev-Drakhlin A, Williams P, Carter C, Gupta S, Steinberg E, Loriot Y, Bellmunt J, Grivas P, Rosenberg J, van der Heijden MS, Galsky MD, Powles T, Mariathasan S, Banchereau R. Hamidi H, et al. Among authors: powles t. Cancer Cell. 2024 Dec 9;42(12):2098-2112.e4. doi: 10.1016/j.ccell.2024.10.016. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577421
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Gedye C, Harrison DJ, Kaplan R, Mulhere S, Nathan P, Patel G, Patel J, Plant H, Ritchie A, Rush H, Shakeshaft C, Stockler MR, Suarez C, Thompson J, Thorogood N, Venugopal B, Parmar MKB. Meade A, et al. Among authors: powles t. Contemp Clin Trials Commun. 2024 Oct 18;42:101381. doi: 10.1016/j.conctc.2024.101381. eCollection 2024 Dec. Contemp Clin Trials Commun. 2024. PMID: 39555240 Free PMC article.
845 results